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Abstract
Glucose metabolism is of vital importance in normal brain
function. Evidence indicates that glycolysis, in addition to
production of ATP, plays an important role in maintaining
normal synaptic function. In an effort to understand the
potential involvement of a glycolytic intermediate(s) in syn-
aptic function, we have prepared [3-32P]1,3-bisphosphogly-
cerate and [32P]3-phosphoglycerate and sought their
interaction with a specific nerve-ending protein. We have
found that a 29-kDa protein is the major component labeled
with either [3-32P]1,3-bisphosphoglycerate or [32P]3-phos-
phoglycerate. The protein was identified as monophospho-
glycerate mutase (PGAM). This labeling was remarkably high
in the brain and synaptosomal cytosol fraction, consistent with
the importance of glycolysis in synaptic function. Of interest,
fructose-2,6-bisphosphate (Fru-2,6-P2) inhibited PGAM
phosphorylation and enzyme activity. Moreover, Fru-2,6-P2
potently stimulated release of [32P]phosphate from the
32P-labeled PGAM (EC50 ¼ 1 lM), suggesting that apparent
reduction of PGAM phosphorylation and enzyme activity by
Fru-2,6-P2 may be due to stimulation of dephosphorylation of
PGAM. The significance of these findings is discussed.
Keywords: 1,3-bisphosphoglycerate, fructose-2,6-bisphos-
phate, glycolysis, nerve ending, phosphoglycerate mutase.
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Glucose metabolism is of paramount importance in brain
function. Cerebral energy is derived from glucose under
normal conditions (Siesjo 1978). Hence, the necessity for
glucose in brain function had been considered solely due to
ATP production. However, evidence has accumulated indi-
cating that hypoglycemia leads to neuronal dysfunction, as
judged by abnormal electroencephalogram and population
spikes, as well as to abnormal behavior, long before cerebral
ATP is depleted (Dirks et al. 1980; Cox and Bachelard 1982;
Ghajar et al. 1982). This suggests that sustaining global
cellular ATP at the normal level would not substitute for the
glucose metabolism requirement. Morino et al. (1991) have
shown that [1-32P]1,3-bisphosphoglycerate (1,3-BPG), a
high energy glycolytic intermediate, can serve as a [32P]
phosphate donor to a 72-kDa protein. These lines of evidence
suggest that glycolysis plays an important role, distinct from
that in ATP production, in maintaining normal synaptic
function. In this study, we have devised a method for
preparation of [3-32P]1,3-BPG, as well as [32P]3-phospho-
glycerate (3-PG), and sought their interaction with a
specific protein(s), in particular in the nerve ending, since
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activity-dependent increase in glucose metabolism largely
occurs in the nerve terminal. We demonstrate that a 29-kDa
protein is labeled as the major component in the synaptosomal
cytosol (synsol) fraction, and present evidence that the labeled
29-kDa protein is monophosphoglycerate mutase (PGAM).
Among non-substrate substances, fructose-2,6-bisphosphate
(Fru-2,6-P2) was found to affect the state of phosphorylation
of the 29-kDa protein and PGAM, as well as PGAM enzyme
activity. The significance of a unique subcellular and tissue
distribution of the labeled 29-kDa protein observed here is
also discussed, together with a potential regulatory role of
Fru-2,6-P2 in glycolysis via PGAM.
Materials and methods
Materials
[c-32P]ATP (6000 Ci/mM) was obtained from Perkin Elmer Life
Sciences (Boston, MA, USA). [32P]Phosphoric acid (Pi, carrier-free)
was purchased from ICN (Irvine, CA). Glycolytic enzymes, their
intermediates and all other chemicals were purchased from Sigma-
Aldrich (St Louis, MO, USA). The affinity-purified polyclonal
antibody (rabbit IgG) specific to human recombinant PGAM type B
(anti-PGAM pAb) was kindly provided by Oriental Yeast Co., Ltd.
(Tokyo, Japan).
Synthesis of [32P]DHAP, [3-32P]1,3-BPG and [32P]3-PG
[32P]Dihydroxyacetone phosphate (DHAP) was prepared by phos-
phorylation of dihydroxyacetone by glycerol kinase with
[c-32P]ATP in a mixture containing 5 mM Tris-HCl (pH 7.0),
40 lM MgSO4, 10 mM dihydroxyacetone, 20 lM [c-
32P]ATP
(6000 Ci/mM) and 0.5 U glycerol kinase (Bacillus stearothermo-
philus). The reaction was performed in a volume of 40 lL at 37C
for 20 min. [3–32P]1,3-BPG was prepared from [32P]DHAP by
conversion to [32P]glyceraldehyde-3-phosphate (GAP) with triose
phosphate isomerase, followed by a GAP dehydrogenase reaction in
the presence of the lactate dehydrogenase-coupled NAD regener-
ating system. The reaction mixture (400 lL) contained 12.5 mM
triethanolamine (pH 8.0), 0.2 mM EDTA, 2 mM NAD, 2 mM Na
pyruvate, 2 mM KH2PO4, 50 lM DHAP, 3.2 U GAP dehydrogenase
(rabbit muscle), 20 U triose phosphate isomerase (rabbit muscle),
10 U lactate dehydrogenase (rabbit muscle) and 40 lL of the
[32P]DHAP reaction mixture. The entire mixture was incubated at
25C for 5 min. For synthesis of [32P]3-PG, a reaction was
performed under the same conditions, except that 0.5 U 3-PG
kinase (Saccharomyces cerevisiae) was added to, and EDTA
removed from, the above reaction mixture. Each reaction mixture
was filtered to remove the enzymes by an Amicon Centricon-10
concentrator (Amicon, Danvers, MA, USA) and put onto a DEAE-
cellulose column (Whatman DE32, 1.2 · 2.2 cm; Watman Inc.,
Clifton, NJ, USA) previously equilibrated with 10 mM glycylgly-
cine, pH 7.4. Elution was carried out with stepwise increases in the
NaCl concentration: 50 mM, 75 mM, 100 mM, 125 mM, 150 mM and
200 mM. DHAP, GAP and inorganic phosphate (Pi) were eluted
with 75 mM NaCl in the same buffer. 3-PG and 1,3-BPG were eluted
with 125 and 150 mM NaCl, respectively, in the same buffer. All the
compounds thus prepared were stored at ) 80C until use.
Analysis of [32P] compounds by HPLC
Radioactive compounds were analyzed by HPLC on a Whatman
Partisil 10 SAX WCS column (4.6 · 250 mm; Beckman Coulter
Inc., Fullerton, CA, USA), comparing their retention times with
those of non-radioactive authentic standards monitored at 214 nm.
The column was equilibrated with 0.4 M sodium phosphate buffer
(pH 3.2), and glycolytic intermediates and nucleotides were eluted
isocratically, as described previously (Morino et al. 1991). Retent-
ion times for glycolytic intermediates were 4.1 min for DHAP and
GAP, 5.3 min for Pi, 5.9 min for 2-phosphoglycerate (2-PG) and 3-
PG, 6.0 min for ADP, 7.4 min for phosphoenolpyruvate (PEP),
15.4 min for 1,3-BPG and 30.0 min for ATP.
Preparation of subcellular fractions
Subcellular fractions of bovine brain were prepared as described
previously (Ueda et al. 1979). The plasma membrane preparation
used in this study was the synaptic plasma membrane M-1 (0.9)
fraction obtained upon sucrose density gradient centrifugation.
Cytosolic fractions of various rat tissues were prepared as described
previously (Ueda and Plagens 1987). Protein concentration was
determined by the method of Bradford (1976) with a Coomassie
Protein Assay Reagent Kit (Pierce Chemical Co., Rockford, IL,
USA) with bovine serum albumin as standard protein.
Protein labeling with [3-32P]1,3-BPG and [32P]3-PG
For the assay for 32P-labeling of protein, the synsol fraction (30 lg
protein) was pre-incubated at 37C for 30 s in 27 lL 5 mM Tris-
maleate (pH 7.4). The reaction was initiated by the addition of 3 lL
[3-32P]1,3-BPG or [32P]3-PG (240 Ci/mM) to the final concentration
of 140 nM, unless otherwise stated, and allowed to continue for 10 s.
Whenever [32P]3-PG was used, 125 nM 2,3-BPG and 1 mM MgSO4
were included. For the dephosphorylation assay of 32P-labeled
protein, protein was labeled with [32P] compounds under the same
conditions, followed by removal of unreacted [32P] compounds with
an Amicon Centricon-10 concentrator. 32P-labeled protein (30 lg)
was incubated at 37C for 10 s in a mixture (final volume 30 lL)
containing 5 mM Tris-maleate (pH 7.4), and indicated concentra-
tions of fructose-1,6-bisphosphate (Fru-1,6-P2) or fructose-2,6-
bisphosphate (Fru-2,6-P2). The reaction was terminated by addition
of 10 lL sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS–PAGE) sample buffer, and aliquots (25 lL) were subjected to
SDS–PAGE (12% acrylamide) according to the method of Laemmli
(1970), except for omission of sample boiling. Autoradiography was
carried out as described previously (Morino et al. 1991) and the
amounts of 32P-labeled protein estimated using an imaging analyzer
(Bio-Rad Gel Doc 2000; Bio-Rad Laboratories, Hercules, CA,
USA). In some experiments, purified rabbit muscle PGAM (Sigma-
Aldrich, 0.48 U) was used instead of 30 lg synsol protein, and
incubated in a reaction mixture containing 5 mM Tris-maleate
(pH 7.4), 0.1 mM MgSO4, 125 nM 2,3-bisphosphoglycerate (2,3-
BPG) and 140 nM (240 Ci/mM) [32P]3-PG.
Immunoprecipitation
Anti-PGAM pAb (10 lg) was absorbed on immobilized protein G
(0.1 mL as 50% slurry) and chemically cross-linked using the Seize
X mammalian immunoprecipitation kit (Pierce). The synsol fraction
(100 lg protein) was incubated at 37C for 10 s in a mixture (final
volume 100 lL) containing 5 mM Tris-maleate (pH 7.4) and
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140 nM (240 Ci/mM) [3-32P]1,3-BPG or [32P]3-PG. When [32P]3-
PG was used, 125 nM 2,3-BPG and 1 mM MgSO4 were included.
The reaction mixtures were subjected to immunoprecipitation with
immobilized anti-PGAM pAb according to the manufacturer’s
protocol. Aliquots (20 lL) were subjected to SDS–PAGE (12%
acrylamide) according to the method of Laemmli (1970), except for
omission of sample boiling, followed by autoradiography as
described previously (Morino et al. 1991).
Assay for PGAM activity
PGAM activity was determined by coupling the formation of 2-PG
from 3-PG with the enolase-, pyruvate kinase- and lactate
dehydrogenase-catalyzed reactions, according to the method recom-
mended by the International Committee for Standardization in
Haematology (Beutler et al. 1977). Briefly, 100 lg protein of synsol
or 0.2 U purified PGAM were incubated in a reaction mixture (final
volume, 1 mL) containing 0.1 M Tris-HCl/0.5 mM EDTA (pH 8.0),
2 mM MgCl2, 100 mM KCl, 0.2 mM NADH, 1.5 mM neutralized
ADP (with NaOH), 10 lM 2,3-BPG, 0.1 mM 3-PG, 1.2 U lactate
dehydrogenase, 1.0 U pyruvate kinase and 1.0 U enolase, at 25C
for 10 min. The enzyme activity was calculated from the rate of
reduction of NADH by monitoring absorbance at 340 nm.
Radioactive product analysis of the 32P-labeled PGAM
de-labeling reaction
PGAM (1.9 mg/mL) was labeled at 37C for 30 s in a buffer
containing 5 mM Tris-maleate (pH 7.4), 125 nM 2,3-BPG, 1 mM
MgSO4 and 0.5 lM [
32P]3-PG (1600 cpm/pM), followed by removal
of unreacted [32P]3-PG with an Amicon Centricon-10 concentrator.
[32P]PGAM (175 lg, 40 042 cpm/mg protein) was pre-incubated at
37C for 30 s in 90 lL 5 mM Tris-maleate (pH 7.4). The reaction
was initiated by the addition of 10 lL Fru-2,6-P2 or 3-PG to
indicated final concentrations and allowed to continue for 10 s. The
reaction was terminated by addition of 100 lL 30% trichloroacetic
acid and centrifuged at 14 000 gmax at 4C. Aliquots (180 lL) of
the supernatant fluid were analyzed by HPLC as described above.
To analyze the effect of various concentrations of Fru-2,6-P2,
[32P]PGAM (25 lg) was incubated with indicated concentrations of
Fru-2,6-P2 under the same conditions.
Time course of [32P]phosphate release from [32P]PGAM
[32P]PGAM (25 lg) was incubated in the absence or presence of
indicated concentrations of Fru-2,6-P2 at 0C for various periods.
Radioactivity of the supernatant fluid obtained upon centrifugation
of the trichloroacetic acid-treated reaction mixture was determined
in a Beckman LS 6500 scintillation spectrophotometer (Beckman
Coulter Inc., Fullerton, CA, USA).
Kinetics study of PGAM 32P-labeling
PGAM (100 lg) was pre-incubated at 37C for 30 s in 90 lL of
reaction mixture containing 5 mM Tris-maleate (pH 7.4), 125 nM
2,3-BPG, 1 mM MgSO4 and indicated concentrations of Fru-2,6-P2.
The reaction was initiated by the addition of 10 lL [32P]3-PG to
indicated final concentrations and allowed to continue for 10 s. The
reaction was terminated by addition of 100 lL 30% trichloroacetic
acid and centrifuged at 14 000 gmax at 4C. The pelleted protein was
washed with 70% ethanol and radioactivity determined in a
scintillation spectrophotometer.
Results
Labeling synsol protein with [3-32P]1,3-BPG
and time course
When the synsol fraction was incubated with [3-32P]1,3-
BPG, it exhibited the 29-kDa protein as the major labeled
protein, as shown in Fig. 1. Incorporation of 32P into the
protein is dependent on the concentration of [3-32P]1,3-BPG
and protein concentration (Fig. 1). As glucose depletion-
induced abnormal changes in electroencephalogram and
behavior occur within minutes, as does recovery from these
deficits observed upon glucose infusion, modification of a
protein(s) involved in the mechanism underlying glycolysis-
dependent synaptic transmission would have to be relatively
rapid, as would its de-modification. Time course of 29-kDa
protein labeling and de-labeling is shown in Fig. 2. While the
initial rate of labeling is temperature-dependent, the maximal
level of labeling is about the same with both incubations at
37C and 0C (Fig. 2). At 37C, 32P-labeling occurs rapidly
with s1/2 of approximately 4 s, whereas the reaction at 0C is
about 10 times slower, with s1/2 of approximately 45 s. Upon
prolonged incubation, the 29-kDa 32P-protein is de-labeled;
at 37C, de-labeling starts at 2 min, with s1/2 of approxi-
mately 20 min, and at 0C, it takes place after 15 min.
Subcellular and tissue distribution
In order to determine the subcellular distribution of
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Fig. 1 Labeling of 29-kDa protein with [3-32P]1,3-BPG in bovine
synsol. The synsol fraction was incubated with [3-32P]1,3-BPG at 37C
for 10 s and aliquots (18.8 lL) were subjected to SDS–PAGE (12%
acrylamide), followed by autoradiography, as described in Materials
and methods. The autoradiogram shown is representative of results
obtained from three separate experiments.
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microsomal, synaptic vesicle and plasma membrane fractions
were analyzed for labeling with [3-32P]1,3-BPG. As shown
in Fig. 3(a), the highest level of labeling was observed in the
synsol fraction, followed by the pericaryal (cell body) cytosol
fraction and the microsomal fraction. The synaptic vesicle
and plasma membrane fractions labeled the 29-kDa protein
to a minimal extent. In order to determine tissue distribution,
various tissues including brain, heart, lung, spleen, pancreas,
kidney, liver, muscle and adrenal were homogenized under
hypotonic conditions, and the soluble fraction obtained upon
ultracentrifugation was analyzed for 29-kDa protein labeling
with [3-32P]1,3-BPG. Brain and the fast-twitch muscle
extensor digitorum longus (EDL) exhibited the most intense
labeling of 29-kDa protein among all the tissues examined,
followed by pancreas (Fig. 3b). The protein was labeled to a
much smaller extent in the spleen, the slow-twitch muscle
soleus (SOL) and adrenal. The 29-kDa protein in the heart,
lung, kidney and liver was minimally labeled. Similar
labeling patterns were observed when tissues were incubated
with [32P]3-PG in the presence of 125 nM 2,3-BPG (data not
shown).
Effect of glycolytic intermediates and related
compounds on labeling of 29-kDa protein
In an effort to explore the possibility that the interaction of
the 29-kDa protein with 1,3-BPG, the most minor glycolytic
intermediate, is subject to regulation by a step in glucose
metabolism, we tested various glycolytic intermediates for
the ability to affect 29-kDa protein labeling. As shown in
Fig. 4, the 29-kDa protein labeling was greatly reduced by
3-PG, 2-PG and PEP. Interestingly, Fru-2,6-P2 also exhibited
a marked inhibition; however, its analog Fru-1,6-P2 was less
effective. The 3-PG close analogs GAP, glycerol-3-phosphate
and glycerate had no significant effect, however. The effect
of PEP could be due to its conversion to 2-PG by enolase
present in the synsol preparation.
The strong diminishing effect of 3-PG and 2-PG on
29-kDa protein labeling suggested that this might be PGAM
(for review, see Rose 1980; Fothergill-Gilmore and Watson
1989). If that were the case, [3-32P]1,3-BPG should have
been converted to [32P]3-PG by 3-PG kinase present in the
synsol, which contains some endogenous ADP. In order to
determine whether this is the case, we analyzed potential
reaction products derived from [3-32P]1,3-BPG upon incu-
bation for various times, as shown in Fig. 5. Indeed,
[3-32P]1,3-BPG was rapidly metabolized to [32P]3-PG/
[32P]2-PG and [32P]PEP, indicating the presence of 3-PG
kinase, PGAM and enolase in the synsol. This suggests that
non-radioactive 2-PG and PEP, when added to the synsol,
would be converted to 3-PG, causing isotopic dilution of
[32P]3-PG. Thus, the ‘apparent inhibitory’ effect of 3-PG,
2-PG and PEP on labeling of the 29-kDa protein would be
due to isotopic dilution of [32P]3-PG. These observations and
considerations support the notion that the 29-kDa protein is
PGAM interacting with [32P]3-PG. In order to provide
further supporting evidence, the ability of [32P]3-PG to label
the 29-kDa protein was compared with that of [3-32P]1,3-
BPG. As shown in Fig. 6, [32P]3-PG was more effective than
[3-32P]1,3-BPG in labeling the 29-kDa protein. This differ-
ential effect is larger at 0C than at 37C, probably due to a
decreased rate of conversion of [3-32P]1,3-BPG to [32P]3-PG
at 0C. These results argue for the notion that [32P]1,3-BPG
is converted to [32P]3-PG and then interacts with PGAM,
forming the phosphorylated enzyme intermediate.
Identification of the 29-kDa labeled protein as PGAM
The relative molecular weight (Mr) of the labeled 29-kDa
protein in the synsol fraction was first compared with that of
purified PGAM phosphorylated with [32P]3-PG. As shown in
Fig. 7(a), the Mrs of both proteins were indistinguishable, as




































































Fig. 2 Time course and temperature dependency of labeling of
29-kDa protein with [3-32P]1,3-BPG. The synsol fraction (1 mg/mL)
was incubated with 140 nM [3-32P]1,3-BPG at 37C or 0C for the
indicated periods. Aliquots (18.8 lL) were subjected to SDS–PAGE
(12%), followed by autoradiography. The level of 29-kDa 32P-labeled
protein during short [(a) approximately 60 s] and long [(b) approxi-
mately 30 min] incubation periods was estimated using an image
analyzer as described in Materials and methods. Values are the mean ±
SD of three experiments.
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substantially reduced by 3-PG. Fru-2,6-P2 also affected
phosphorylation of both proteins. Moreover, the 29-kDa
protein in the synsol fraction labeled with either [3-32P]1,3-
BPG or [32P]3-PG was immunoprecipitated by antibodies to
recombinant PGAM (Fig. 7b).
The effect of glycolytic intermediates and related com-
pounds on 32P-labeling of purified PGAM was examined, in
comparison with the effect on 32P-labeling of the synsol,
29-kDa protein. As shown in Fig. 8, the inhibition pattern
with various glycolytic intermediates and related compounds
is very similar to that observed with labeling the 29-kDa
protein in the synsol (Fig. 4), with the exception of the effect
of PEP. Although phosphorylation of purified PGAM was
inhibited by 3-PG and 2-PG, it was not affected by PEP
(Fig. 8). This is most likely because purified PGAM is
largely free of enolase; thus, PEP would not have been
converted to 2-PG and hence, not to 3-PG. As a result,
isotopic dilution of [32P]3-PG would not have occurred.
Tissue distribution in 32P-labeling of the cytosolic 29-kDa
protein (Fig. 3) was quite striking. In order to determine
whether this represents the tissue distribution of PGAM, the
cytosolic fractions of various tissues were assayed for PGAM
activity. As shown in Fig. 9, the specific enzyme activity
pattern among various tissues tested was similar to the
specific 32P-labeling activity pattern of the cytosolic 29-kDa
protein. EDL muscle revealed the highest specific enzyme
activity, followed by brain and pancreas; heart, lung, kidney
and liver showed the lowest enzyme activity. These obser-
vations are consistent with the notion that the cytosolic
















Fig. 3 Subcellular and tissue distributions
of 29-kDa protein labeling with [3-32P]1,3-
BPG. Various subcellular fractions of
bovine brain (a) and total cytosolic fractions
of rat tissue (b) as indicated, each contain-
ing 1 mg/mL), were incubated with 140 nM
[3-32P]1,3-BPG at 37C for 10 s and aliqu-
ots (18.8 lL) subjected to SDS–PAGE
(12%), followed by autoradiography as
described in Materials and methods. The
autoradiograph shown is representative of
results obtained from three separate










Fig. 4 Effect of various glycolytic intermediates and related com-
pounds on 29-kDa protein labeling in bovine synsol with [3-32P]1,3-
BPG. The synsol fraction (1 mg/mL) was incubated with 140 nM
[3-32P]1,3-BPG at 37C or 0C for 10 s in the absence (control) or
presence of various glycolytic intermediates and related compounds
(50 lM). Aliquots (18.8 lL) were subjected to SDS–PAGE (12%), fol-
lowed by autoradiography. The level of the 29-kDa 32P-labeled protein
was estimated using an image analyzer as described in Materials and
methods, and expressed as the percentage of control value. Values
are the mean ± SD of three experiments. Glu, glucose; Glu-1-P, glu-
cose-1-phosphate; Glu-6-P, glucose-6-phosphate; Glu-1,6-P2, glu-
cose-1,6-bisphosphate; Fru-1-P, fructose-1-phosphate; Fru-6-P,
fructose-6-phosphate; glycerol-3-P, glycerol-3-phosphate.
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Fru-2,6-P2 reduces
32P-labeling of PGAM by enhancing
dephosphorylation
As the inhibitory effect of Fru-2,6-P2 on phosphorylation of
PGAM has not been reported, we further studied this
property of the enzyme, in comparison with its effect on the
29-kDa protein in the synsol. Shown in Fig. 10 is the effect
of various concentrations of Fru-2,6-P2 on PGAM phos-
phorylation. The data indicate that Fru-2,6-P2 quite potently
inhibits labeling of the synsol 29-kDa protein and purified
PGAM with similar potencies (IC50 ¼ 8–9 lM). In contrast,
Fru-1,6-P2 was less effective but exhibited similar potencies
(IC50 ¼ 70–80 lM). Fru-2,6-P2 also inhibited overall
enzyme activity in the purified PGAM preparation and in
the synsol fraction in a similar manner (Fig. 11); however,
the IC50 value of 50 lM was higher than that observed for
inhibition of 32P-labeling. Fru-1,6-P2 also showed similar
inhibitory effects, but with a much lower potency
(IC50 ¼ 1 mM). These observations further argue for the
notion that the synsol 29-kDa protein labeled with
[3-32P]1,3-BPG or [32P]3-PG is PGAM.
In an effort to understand the mechanism of inhibition
by F-2,6-P2, kinetic experiments were carried out on
32P-labeling and enzyme activity of PGAM, each in the
absence or presence of two concentrations of Fru-2,6-P2, as
shown in Fig. 12. The data indicate that Fru-2,6-P2 inhibits
both 32P-labeling and enzyme activity of PGAM in a non-
competitive manner with respect to the substrate 3-PG. The
Ki was calculated to be 42 lM in the
32P-labeling reaction
and 36 lM in the overall enzyme reaction. These data suggest
that Fru-2,6-P2 produces the inhibitory effect by binding to
an allosteric site.
To further understand the action of Fru-2,6-P2, we
explored the possibility that Fru-2,6-P2 enhances
32P-de-
labeling of PGAM. As shown in Fig. 13, the 32P-labeled

























































Fig. 5 Metabolism of [3-32P]1,3-BPG upon bovine synsol. The synsol
fraction (1 mg/mL) was incubated with 140 nM [3-32P]1,3-BPG at 37C
for the indicated periods [(a) approximately 120 s; (b) approximately
30 min]. After the protein was removed by use of an Amicon Centr-
icon-10 concentrator, radioactive compounds were analyzed by HPLC
as described in Materials and methods. The level of each radioactive
compound was calculated as the percentage of total radioactive
compounds. Values are the mean ± SD of three experiments. Pi,










































































Fig. 6 Labeling of 29-kDa protein with [32P]3-PG in comparison with
[3-32P]1,3-BPG. Synsol (1 mg/mL) was incubated with 140 nM
[3-32P]1,3-BPG or 140 nM [32P]3-PG at 37C (a) or 0C (b) for the
indicated periods. Aliquots (18.8 lL) were subjected to SDS–PAGE
(12%), followed by autoradiography. The level of 29-kDa 32P-labeled
protein was estimated using an image analyzer as described in Mate-
rials and methods. Values are the mean ± SD of three experiments.
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Fig. 7 Identification of the 29-kDa protein
as PGAM. (a) Comparison of the 29-kDa
protein in the synsol labeled with [32P]3-PG
and purified PGAM labeled with [32P]3-PG.
The synsol (1 mg/mL) or purified PGAM
(PGAM; 16 unit/mL) was incubated with
140 nM [32P]3-PG at 37C for 10 s in the
absence or presence of 50 lM 3-PG or Fru-
2,6-P2. Aliquots (18.8 lL) were subjected to
SDS–PAGE (12%), followed by autoradi-
ography as described in Materials and
methods. CBB, Coomassie Brilliant Blue.
(b) Immunoprecipitation of the 29-kDa pro-
tein with anti-PGAM polyclonal antibodies.
The synsol (1 mg/mL) was incubated with
140 nM [3-32P]1,3-BPG or [32P]3-PG at
37C for 10 s and immunoprecipitated with
anti-PGAM polyclonal antibodies (anti-
PGAM pAb) or non-immunized rabbit IgG,
followed by autoradiography as described
in Materials and methods. The result shown










Fig. 8 Effect of various glycolytic intermediates and related com-
pounds on 32P-labeling of purified PGAM with [32P]3-PG. Purified
PGAM (16 unit/mL) was incubated with 140 nM [3-32P]1,3-BPG at
37C for 10 s in the absence (control) or presence of various glycolytic
intermediates and related compounds (50 lM). Aliquots (18.8 lL) were
subjected to SDS–PAGE (12%), followed by autoradiography. The
level of 32P-labeled PGAM was estimated as the percentage of control
value using an image analyzer as described in Materials and methods.
Values are the mean ± SD of three experiments. Abbreviations are






Fig. 9 PGAM activity in various rat tissues. Aliquots (100 lg) of var-
ious rat tissue whole cytosolic fractions were assayed for PGAM
activity, as described in Materials and methods. Values are the
mean ± SD of three experiments. SOL, soleus; EDL, extensor dig-
itorum longus.
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presence of 50 lM Fru-2,6-P2, as well as in the presence of
3-PG, not only at 37C but also at 0C. The effect of various
concentrations of Fru-2,6-P2 and Fru-1,6-P2 on de-labeling
of the [32P]-labeled 29-kDa protein was examined and
compared with the effect on de-labeling of purified
32P-labeled PGAM (Fig. 14). Fru-2,6-P2 was equally potent
in the de-labeling of both the 29-kDa protein and PGAM; the
concentration required to cause 50% de-labeling was deter-
mined to be 1 lM in both cases. Thus, Fru-2,6-P2 is far more
effective in causing de-labeling than in inhibiting [32P]-
labeling of the 29-kDa protein.
The radioactive product of the de-labeling reaction was
analyzed by HPLC. As shown in Fig. 15(a), incubation of
32P-labeled purified PGAM in the presence of Fru-2,6-P2
resulted in release of [32P]Pi, whereas the presence of
unlabeled 3-PG produced [32P]3-PG or [32P]2-PG, or both.
The amount of [32P]Pi released in the presence of 50 lM
Fru-2,6-P2 was essentially the same as the amount of
[32P]3-PG/2-PG formed in the presence of 50 lM 3-PG.
[32P]Pi was released in a time-dependent manner
(Fig. 15b). In order to correlate [32P]Pi release with
PGAM de-labeling, the effect of various concentrations
of Fru-2,6-P2 on [
32P]Pi release was examined (Fig. 15b)
in comparison with the effect on PGAM de-labeling. The
figure shows that the sensitivity of [32P]Pi release from
32P-labeled PGAM to Fru-2,6-P2 is indistinguishable from
that of PGAM de-labeling to Fru-2,6-P2 (Fig. 14b). The
concentration required for 50% maximal release was 1 lM.
These results indicate that 32P-labeled PGAM represents
[32P]phosphorylated PGAM, and that Fru-2,6-P2 stimulates
transfer of [32P]phosphate to water, thus causing a
phosphatase reaction, while 3-PG-stimulated de-labeling

































































Fig. 10 Effect of various concentrations of fructose bisphosphates on
32P-labeling of the 29-kDa protein in synsol and purified PGAM with
[32P]3-PG. The synsol fraction [1 mg/mL (a)] or PGAM [16 unit/mL (b)]
was incubated with 140 nM [32P]3-PG at 37C for 10 s in the absence
(control) or presence of Fru-2,6-P2 or Fru-1,6-P2 at the indicated
concentrations. Aliquots (18.8 lL) were subjected to SDS–PAGE
(12%), followed by autoradiography. The level of 32P-labeled protein
was estimated as the percentage of control value using an image
analyzer as described in Materials and methods. Values are the mean ±



























































Fig. 11 Effect of various concentrations of fructose bisphosphates on
PGAM activity in synsol and purified PGAM. PGAM activity in the
synsol fraction [0.1 mg/mL, approximately 3 unit/mg protein (a) or
purified PGAM 0.2 unit/mL (b)] was measured in the absence (control)
or presence of Fru-1,6-P2 or Fru-2,6-P2 at the indicated concentra-
tions, as described in Materials and methods. Values are the mean ±
SD of three experiments.
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Discussion
In an effort to understand a potential biochemical link
between glycolysis and synaptic function, in a previous study
we sought a glycolytic intermediate-dependent protein
phosphorylation system using [c-32P]ATP. Evidence was
obtained for the existence of phosphoglycerate-dependent
phosphorylation of 72-kDa and 155-kDa proteins in mam-
malian brain (Ueda and Plagens 1987; Morino et al. 1991).
The 72-kDa protein was subsequently shown to be directly
phosphorylated with [1-32P]1,3-BPG and identified as glu-
cose 1,6-bisphosphate synthase (Morino et al. 1991). In
contrast, the 155-kDa protein was not subject to direct
phosphorylation with [1-32P]1,3-BPG; hence it is thought to
be phosphorylated at the expense of [c-32P]ATP by ‘3-PG-
dependent kinase.’ Although both proteins are enriched in
the synsol fraction, their functional role in synaptic function
remains to be elucidated.
In the present study, we synthesized [3-32P]1,3-BPG and
sought a nerve terminal protein(s) which may be modified by
a mechanism involving the transfer of [3-32P]phosphate or
the phosphoglyceroyl moiety. We provided evidence that the
major protein labeled with [3-32P]1,3-BPG, under the assay
conditions used, is PGAM; the 72-kDa and 155-kDa proteins
were not labeled with [3-32P]1,3-BPG, in contrast to labeling
with [1-32P]1,3-BPG or [c-32P]ATP, indicating that neither
3-phosphate nor the 3-phosphoglyceroyl group of 1,3-BPG is
transferred onto these proteins. This labeled protein has a
subunit molecular weight of approximately 29 000 and is
rapidly labeled by both [3-32P]1,3-BPG and [32P]3-PG.
However, this protein was not labeled with [1-32P]1,3-BPG
(Morino et al. 1991), indicating that 1-phosphate of 1,3-BPG
is not transferred onto the 29-kDa protein. The labeling with
[3-32P]1,3-BPG is most potently reduced by 3-PG, 2-PG and
Fru-2,6-P2 of all the agents tested. [
32P]3-PG-labeled PGAM
undergoes fast de-labeling in the presence of 3-PG or 2-PG.
This is in agreement with Rose and Dube (1976), who have
shown that both PGAM phosphorylation and dephosphory-
lation occur rapidly. Moreover, the labeled protein is subject
to immunoprecipitation with affinity-purified anti-PGAM
IgG. These observations indicate that the [3-32P]1,3-BPG or
[32P]3-PG-labeled 29-kDa protein is identical to PGAM.
Thus, labeling and de-labeling of the synsol 29-kDa protein
would represent phosphorylation and dephosphorylation of
the active site histidine residue of PGAM (Rose 1970, 1980).
An interesting finding in this study is that Fru-2,6-P2
inhibits both phosphorylation (IC50 ¼ 10 lM) and enzymatic
activity of PGAM (IC50 ¼ 50 lM). Fru-2,6-P2 also acceler-
ates dephosphorylation of PGAM (EC50 ¼ 1 lM). Fru-2,6-P2
is more effective in dephosphorylating PGAM than in inhibit-

































































Fig. 12 Kinetics of the 32P-labeling and activity of purified PGAM in
the absence or presence of Fru-2,6-P2. (a) PGAM (1 mg/mL) was
incubated with various concentrations of [32P]3-PG at 37C for 10 s in
the absence or presence of indicated concentrations of Fru-2,6-P2,
and the level of 32P-labeled protein determined. (b) PGAM activity was
determined with various concentrations of 3-PG in the absence or
presence of indicated concentrations of Fru-2,6-P2, as described in
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Fig. 13 Fru-2,6-P2 as well as 3-PG stimulates de-labeling of
32P-labeled 29-kDa protein in synsol. The synsol fraction was incu-
bated with 140 nM [32P]3-PG at 37C for 10 s. After unreacted
[32P]3-PG was removed by use of an Amicon Centricon-10 concen-
trator, 32P-labeled protein (1 mg/mL) was incubated at 0 or 37C for
the indicated time in the absence or presence of 50 lM Fru-2,6-P2 or
3-PG. Aliquots (18.8 lL) were subjected to SDS–PAGE (12%), fol-
lowed by autoradiography, as described in Materials and methods.
The result shown is representative of three separate experiments.
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effect of Fru-2,6-P2 on PGAM phosphorylation could be
largely due to its ability to enhance dephosphorylation. In
contrast to the case with 3-PG, transfer of radioactive
phosphate to Fru-2,6-P2 was not observed. In fact, Fru-2,6-P2
stimulated release of inorganic [32P]phosphate from the
[32P]phosphoenzyme (Fig. 15). Kinetic experiments
(Fig. 12) suggest that Fru-2,6-P2 binds to an allosteric site.
These experiments suggest that, upon binding of Fru-2,6-P2,
PGAM could alter its conformation, exposing the phospho-
histidine moiety to the aqueous environment so that the
phosphoenzyme is hydrolyzed to inorganic phosphate and
dephosphoenzyme.
Fru-2,6-P2 is known as a regulator of glycolysis in the
liver (Van Schaftingen 1987; Okar and Lange 1999). It acts
as an allosteric activator of phosphofructokinase 1 (PFK-1),
increasing the enzyme’s affinity for fructose 6-phosphate
(Van Schaftingen et al. 1981). In the liver, the biosynthesis
of Fru-2,6-P2 is achieved by phosphofructokinase-2 (PFK-2),
whose activity is regulated via phosphorylation of a serine
residue by cAMP-dependent protein kinase (Okar et al.
2001). In the brain, however, PFK-2 activity is not altered as
a result of phosphorylation by cAMP-dependent protein
kinase (Ventura et al. 1991; Ventura et al. 1992). Nonethe-
less, Fru-2,6-P2 acts as a positive allosteric effector of brain
PFK-1 and is thought to play an essential role in the basal
activation of the brain enzyme under a variety of physiolo-
gical conditions (Foe and Kemp 1985; Ventura et al. 1991).
Brain PFK-1, maximally activated with 4–6 lM Fru-2,6-P2,
is saturated with Fru-2,6-P2 under normal conditions (Foe
and Kemp 1984; Yamamoto et al. 1990; Ambrosio et al.
1991, 1992; Ventura et al. 1991; Anglard et al. 1992; Kasten
et al. 1993). Thus, PFK-1 may not be subject to regulation
by Fru-2,6-P2 in the brain under normal conditions (Ventura
et al. 1992).
Fru-2,6-P2 inhibits PGAM enzyme activity with a Ki value
of 36 lM. The steady-state tissue level of Fru-2,6-P2 in the
brain is 5–16 nM/g tissue (Yamamoto et al. 1990; Ambrosio
et al. 1991, 1992; Ventura et al. 1991; Kasten et al. 1993).
Neuronal Fru-2,6-P2 concentration can be increased three to
fourfold by treatment with either ACTH or 12-O-tetradeca-
noylphorbol 13-acetate (Anglard et al. 1992). Under these
conditions, Fru-2,6-P2 might exert an inhibitory effect on
PGAM. Thus, PGAM could be subject to regulation by Fru-
2,6-P2 under certain conditions. Under normal conditions,
neuronal PFK-1 would most likely be in a fully activated
state in the presence of saturating concentrations of Fru-2,6-P2.
When PGAM is inhibited by increased concentrations of Fru-
2,6-P2, the glycolytic intermediate 3-PG would be accumu-
lated. One of the consequences of 3-PG elevation would be
to activate 3-PG-dependent protein kinase, leading to
phosphorylation of the synsol 155-kDa protein (Ueda and
Plagens 1987; Morino et al. 1991). Thus, it is plausible that
glycolysis up to the step of 3-PG production, Fru-2,6-P2-
induced accumulation of 3-PG and 3-PG-dependent phos-
phorylation of the 155-kDa protein are all involved in the
mechanism underlying glycolysis-dependent synaptic trans-
mission. Further studies are required to determine the
significance of PGAM inhibition by Fru-2,6-P2.
Another interesting observation is that the level of PGAM
labeling with [3-32P]1,3-BPG, as well as the specific enzyme
activity of PGAM, is remarkably high in the brain and the
fast-twitch muscle extensor digitorum longus; of brain
subcellular fractions, the synsol exhibited the most prominent
labeling. The amount of labeled PGAM in the cell body
cytosol fraction is substantially smaller. These observations
suggest that the rate of glycolysis might be high in
subcellular regions where either neurotransmitters or hor-

































































Fig. 14 Effect of various concentrations of fructose bisphosphates on
the dephosphorylation of 32P-labeling of 29-kDa protein in synsol and
purified PGAM. The synsol fraction [1 mg/mL (a)] or purified PGAM
[16 unit/mL (b)] was incubated with 140 nM [32P]3-PG at 37C for 10 s.
After unreacted [32P]3-PG was removed by use of an Amicon Centr-
icon-10 concentrator, 32P-labeled protein of synsol (1 mg/mL) or
PGAM (0.016 unit/mL) was incubated at 37C for 10 s in the absence
(control) or presence of Fru-2,6-P2 or Fru-1,6-P2 at the indicated
concentrations. Aliquots (18.8 lL) were subjected to SDS–PAGE
(12%), followed by autoradiography. The level of 32P-labeled protein
was estimated as the percentage of control value, using an image
analyzer as described in Materials and methods. Values are the mean ±
SD of three experiments.
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ending, there is a high demand for glycolytically-produced
ATP, rather than ATP produced in mitochondria, in order to
meet quick demands for energy; duly responding transmitter
release is thus sustained. In further support of this notion is
evidence that the nerve ending is rich in glycolytic enzymes
(Knull 1978); some are associated with the synaptic plasma
membrane via actin (Knull 1980), which would allow
glycolysis to occur efficiently at high energy-requiring pre-
synaptic membrane sites. Compatible with this concept, we
have recently obtained evidence indicating that glycolytically-
generated ATP is utilized for neurotransmitter uptake into
the releasable vesicular pool (Ikemoto et al. 2003). Thus,
acute depletion of glycolytically-produced ATP, without
much affecting the total reserve of ATP which is largely
made in mitochondria, would diminish neurotransmitter
release. This might provide an explanation for the critical
importance of glycolysis in synaptic transmission. The fast-
twitch fiber is far richer in glycolytic enzymes, including
PGAM, than the slow-twitch fiber of the soleus (Baldwin
et al. 1973; Andres et al. 1989), and is thought to mainly
harness glycolytically-produced ATP for rapid muscle
movement (Holloszy and Booth 1976). These lines of
evidence are consistent with the notion that rapid, energy-
consuming, cellular processes rely on glycolytically-pro-
duced ATP.
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